Immune Cell Dysfunction in Severe Alcoholic Hepatitis

Hepatitis Clinical Trial

Official title:

Immune Cell Dysfunction in Severe Alcoholic Hepatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02275195
• Other study ID #: B663
• Status: Recruiting
• Start date: November 2013
• Est. completion date: December 2024

Study information

• Verified date: January 2024
• Source: Mid and South Essex NHS Foundation Trust
• Contact: Carol L Alves, BSc, MRes
• Phone: 01268 529400
• Email: Carol.Alves[@]btuh.nhs.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Through bio-sampling this study investigates the relationship between the frequency and function of the cells of a patients immune system and how these change and impact on the outcome of alcoholic hepatitis. the investigators will examine the role of different cells of the immune system and how they may determine the outcome of this condition. The investigators will also look at how established treatment strategies impact on the frequency and function of these cell subsets.

Description:

Through bio-sampling this study investigates the relationship between the frequency and function of the cells of a patients immune system and how these change and impact on the outcome of alcoholic hepatitis. The investigators will examine the role of different cells of the immune system and how they may determine the outcome of this condition. The investigators will also look at how established treatment strategies impact on the frequency and function of these cell subsets.

Alcohol is the most common cause of liver disease in the developed world and results in the death of 2.5 million people annually. It is a causal factor in more than 60 major types of diseases and injuries and approximately 4.5% of the global burden of disease and injury is attributable to alcohol. Acute alcoholic hepatitis (AAH) is perhaps the most florid form of ALD and the leading cause of mortality in these patients is the development of sepsis which occurs in up to 40% of these patients and has a mortality rate of 50%.

By gaining a better understanding of the relationship between elements of the immune system and the progression to severe alcoholic hepatitis, it will allow the formulation of more effective treatment strategies for this condition.

Patients who agree to participate in this study will have an extra 40mls of blood drawn for scientific studies at the same time as routine blood samples are taken as part of their ongoing care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 18-65 years

2. Patients presented with severe alcoholic hepatitis with a Maddrey score (discriminant function) of >32 (The Maddrey score uses various blood results on a patient to define the severity of alcoholic hepatitis e.g.bilirubin etc).

3. Ongoing abuse of alcohol (drinking in excess of 28 units/wk)

Exclusion Criteria:

1. Co-infection with HIV/Hepatitis B / Hepatitis C virus infection.

2. Patients with autoimmune liver disease.

3. Patients with metabolic liver disease.

4. Patients with significant psychiatric and/or neurological co-morbidity.

5. Hepatocellular carcinoma or other neoplastic disease

6. Pregnancy or breast feeding of infants.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis, Alcoholic

Locations

Country	Name	City	State
United Kingdom	Basildon Hospital	Basildon	Essex

Sponsors (1)

Lead Sponsor	Collaborator
Mid and South Essex NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine and changes to immune cell responses for outpatients with Alcoholic Hepatitis	Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis	Participants will be followed-up during thier hospital stay, which averages 4 weeks
Secondary	Change from baseline to end of study in flow cytometry for patients with Alcoholic Hepatitis	Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis	on average 4 weeks
Secondary	Change from baseline to end of study in real time PCR for patients with Alcoholic Hepatitis	Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis	On average 4 weks
Secondary	Change from baseline to end of study in cell cultures for patients with Alcoholic Hepatitis	Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis	on average 4 weeks